Late isolated ocular toxoplasmosis in a belatacept-treated kidney transplant patient

Transpl Int. 2016 Dec;29(12):1352-1353. doi: 10.1111/tri.12853. Epub 2016 Sep 30.

Authors

Luca Lanfranco¹, Priscille Olle Delahaye², Gaelle Dorr^{1

3}, Arnaud Del Bello¹, Nassim Kamar^{1

3

4}

Affiliations

¹ Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
² Department of Ophthalmology, CHU Purpan, Toulouse, France.
³ Université Paul Sabatier, Toulouse, France.
⁴ INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France.

PMID: 27614031
DOI: 10.1111/tri.12853

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Abatacept / adverse effects*
Abatacept / therapeutic use*
Aged
Cyclophosphamide / therapeutic use
Fundus Oculi
Graft Rejection
Humans
Immunoconjugates
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use
Kidney Transplantation*
Male
Renal Insufficiency / immunology
Renal Insufficiency / surgery
Toxoplasma / isolation & purification
Toxoplasmosis, Ocular / diagnosis*
Toxoplasmosis, Ocular / drug therapy
Treatment Outcome
Vasculitis / drug therapy

Substances

Immunoconjugates
Immunosuppressive Agents
Abatacept
Cyclophosphamide